Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Kamilla Begtrup"'
Autor:
Athena Philis‐Tsimikas, Harpreet S. Bajaj, Kamilla Begtrup, Roman Cailleteau, Amoolya Gowda, Ildiko Lingvay, Chantal Mathieu, David Russell‐Jones, Julio Rosenstock
Publikováno v:
Diabetes, obesitymetabolismREFERENCES.
To describe the phase 3a ONWARDS clinical development programme investigating insulin icodec (icodec), a once-weekly basal insulin, including the design and rationale for each of the ONWARDS 1-6 trials.Six randomized controlled trials have been initi
Autor:
null Athena Philis‐Tsimikas, null Harpreet S. Bajaj, null Kamilla Begtrup, null Roman Cailleteau, null Amoolya Gowda, null Ildiko Lingvay, null Chantal Mathieu, null David Russell‐Jones, null Julio Rosenstock
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e36330f5dddc6d2399cb49a0e7baf45
https://doi.org/10.1111/dom.14871/v2/response1
https://doi.org/10.1111/dom.14871/v2/response1
Autor:
Ildiko Lingvay, D. Gouet, Mattis F. Ranthe, Luigi F. Meneghini, Petra Őrsy, Ankur Doshi, Tina Vilsbøll, Kamilla Begtrup
Publikováno v:
Diabetic Medicine
Meneghini, L, Doshi, A, Gouet, D, Vilsbøll, T, Begtrup, K, Őrsy, P, Ranthe, M F & Lingvay, I 2020, ' Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin ', Diabetic Medicine, vol. 37, no. 2, pp. 267-276 . https://doi.org/10.1111/dme.14178
Meneghini, L, Doshi, A, Gouet, D, Vilsbøll, T, Begtrup, K, Őrsy, P, Ranthe, M F & Lingvay, I 2020, ' Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin ', Diabetic Medicine, vol. 37, no. 2, pp. 267-276 . https://doi.org/10.1111/dme.14178
Aims To assess whether people with type 2 diabetes transferring from higher basal insulin doses (> 20 units) to a starting dose of 16 units of insulin degludec/liraglutide (IDegLira) benefit from IDegLira with/without transient loss of glycaemic cont
Publikováno v:
Diabetes. 70
Insulin icodec* (icodec) is a novel once-weekly basal insulin analog in development. This post hoc analysis explored hypoglycemia duration using double-blinded CGM (Dexcom G6®) data from 2 phase 2, randomized, open-label, treat-to-target 16-week tri
Autor:
Julio, Rosenstock, Harpreet S, Bajaj, Andrej, Janež, Robert, Silver, Kamilla, Begtrup, Melissa V, Hansen, Ting, Jia, Ronald, Goldenberg, S, Sakshi
Publikováno v:
The New England journal of medicine. 383(22)
It is thought that a reduction in the frequency of basal insulin injections might facilitate treatment acceptance and adherence among patients with type 2 diabetes. Insulin icodec is a basal insulin analogue designed for once-weekly administration th
Autor:
Cristobal Morales Portillo, Liana K. Billings, Kamilla Begtrup, Robert S. Busch, Athena Philis-Tsimikas, Sarah Eggert, Rakesh Sahay, Natalie Halladin, Stewart B. Harris
Publikováno v:
Diabetes, Obesity & Metabolism
Aim To investigate the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine 100 units/mL (IGlar U100) as add‐on to sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor therapy. Materials and methods In this 26
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0559be315e88346d001e8803474adb8c
https://hdl.handle.net/10668/13562
https://hdl.handle.net/10668/13562
Autor:
Tina Vilsbøll, Allen B. King, Eric S. Kilpatrick, Athena Philis-Tsimikas, Irene H. Langbakke, Kamilla Begtrup
Publikováno v:
King, A B, Philis-Tsimikas, A, Kilpatrick, E S, Langbakke, I H, Begtrup, K & Vilsbøll, T 2017, ' A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges ', Diabetes Technology & Therapeutics, vol. 19, no. 4, pp. 255-264 . https://doi.org/10.1089/dia.2016.0405
Diabetes Technology & Therapeutics
Diabetes Technology & Therapeutics
BACKGROUND: Reducing glycemic fluctuation is important for optimal diabetes management. This post hoc analysis examined glycemic fluctuations and the proportion of subjects achieving recommended blood glucose targets with the fixed ratio combination
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa13b79b5114fb7d91b8e7a884b07bed
https://curis.ku.dk/ws/files/198612554/dia.2016.0405.pdf
https://curis.ku.dk/ws/files/198612554/dia.2016.0405.pdf
Autor:
Trine Welløv Boesgaard, Kamlesh Khunti, Kamilla Begtrup, Viswanathan Mohan, Sunil M Jain, Bipin Sethi
Publikováno v:
Diabetes Therapy
Introduction The efficacy and safety of insulin degludec/liraglutide (IDegLira) has been evaluated in the Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes (DUAL) phase 3 clinical trial program. In this post hoc analysis, we compared
Publikováno v:
Expert Opinion on Pharmacotherapy. 19:317-318